JP2008512457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512457A5 JP2008512457A5 JP2007531262A JP2007531262A JP2008512457A5 JP 2008512457 A5 JP2008512457 A5 JP 2008512457A5 JP 2007531262 A JP2007531262 A JP 2007531262A JP 2007531262 A JP2007531262 A JP 2007531262A JP 2008512457 A5 JP2008512457 A5 JP 2008512457A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- alkoxy
- hydroxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000005843 halogen group Chemical group 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- -1 hydroxy, amino Chemical group 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 5
- 102000009346 Adenosine receptors Human genes 0.000 claims 5
- 108050000203 Adenosine receptors Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 150000001602 bicycloalkyls Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000003106 haloaryl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 2
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 1
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 claims 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000005961 cardioprotection Effects 0.000 claims 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60882304P | 2004-09-09 | 2004-09-09 | |
| PCT/US2005/031678 WO2006031505A1 (en) | 2004-09-09 | 2005-09-02 | Purine derivatives as a3 and a1 adenosine receptor agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012128779A Division JP2012229215A (ja) | 2004-09-09 | 2012-06-06 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008512457A JP2008512457A (ja) | 2008-04-24 |
| JP2008512457A5 true JP2008512457A5 (enExample) | 2008-08-28 |
Family
ID=35517431
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531262A Ceased JP2008512457A (ja) | 2004-09-09 | 2005-09-02 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
| JP2012128779A Withdrawn JP2012229215A (ja) | 2004-09-09 | 2012-06-06 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012128779A Withdrawn JP2012229215A (ja) | 2004-09-09 | 2012-06-06 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7825126B2 (enExample) |
| EP (1) | EP1794162A1 (enExample) |
| JP (2) | JP2008512457A (enExample) |
| KR (1) | KR20070050484A (enExample) |
| CN (1) | CN101056879B (enExample) |
| AU (1) | AU2005285284B2 (enExample) |
| BR (1) | BRPI0515030A (enExample) |
| CA (1) | CA2601996A1 (enExample) |
| IL (1) | IL181716A0 (enExample) |
| WO (1) | WO2006031505A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| HRP20120494T1 (hr) | 2006-04-21 | 2012-08-31 | Novartis Ag | Derivati purina za uporabu kao agonista adenozin a2a receptora |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| ES2526713T3 (es) | 2006-05-23 | 2015-01-14 | University Of Connecticut | Derivados de N-metanocarba para tratar enfermedades cardiacas |
| US7906518B2 (en) * | 2006-06-27 | 2011-03-15 | Cbt Development Limited | Therapeutic compounds |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| WO2008023362A2 (en) * | 2006-08-21 | 2008-02-28 | Can-Fite Biopharma Ltd. | Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| JP2010508835A (ja) * | 2006-11-10 | 2010-03-25 | ノバルティス アーゲー | シクロペンテンジオールモノアセテート誘導体 |
| WO2009006046A1 (en) | 2007-06-29 | 2009-01-08 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Dendrimer conjugates of agonists and antagonists of the gpcr superfamily |
| NZ601866A (en) | 2007-06-29 | 2013-12-20 | Acucela Inc | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
| EP2227234B1 (en) | 2007-10-15 | 2014-05-07 | Can-Fite Biopharma Ltd. | Method for inducing hepatocyte proliferation and uses thereof |
| AU2009231978C1 (en) | 2008-03-31 | 2014-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as A3 adenosine receptor- selective agonists |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| WO2010014921A2 (en) * | 2008-08-01 | 2010-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| EP2507241A1 (en) | 2009-12-02 | 2012-10-10 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Methanocarba adenosine derivatives and dendrimer conjugates thereof |
| PT2539352T (pt) | 2010-02-22 | 2018-01-03 | Univ Connecticut | Composições e métodos para tratar doenças cardíacas |
| WO2011123518A1 (en) | 2010-03-31 | 2011-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
| JP6577165B2 (ja) * | 2011-01-26 | 2019-09-18 | 北京康倍得医▲藥▼技▲術▼▲開▼▲發▼有限公司 | リボフラノシルプリン化合物、その調製方法、およびその使用 |
| EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015080940A1 (en) * | 2013-11-27 | 2015-06-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| CN109310695B (zh) * | 2016-04-21 | 2022-04-01 | 阿斯特罗赛特制药公司 | 治疗神经和心血管病况的化合物和方法 |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR101820909B1 (ko) * | 2017-07-07 | 2018-01-23 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물 |
| US11839615B2 (en) | 2018-02-09 | 2023-12-12 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating addiction and related disorders |
| EP3856741A4 (en) | 2018-09-26 | 2022-06-22 | Astrocyte Pharmaceuticals, Inc. | POLYMORPHOUS COMPOUNDS AND USES THEREOF |
| US20240368164A1 (en) * | 2021-04-28 | 2024-11-07 | Astrocyle Pharmaceuticals, Inc. | Purine nucleosides, their intermediates, and methods of preparation thereof |
| EP4337646A4 (en) | 2021-05-13 | 2025-05-21 | Promega Corporation | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS |
| EP4747254A1 (en) * | 2023-07-17 | 2026-05-27 | The United States of America, as represented by the Secretary, Department of Health and Human Services | <sup2/>? <sub2/>?2b?5-htserotonin receptor antagonists, pharmaceutical compositions thereof, and methods of use thereof |
| CN117503766B (zh) * | 2024-01-04 | 2024-04-26 | 中国康复研究中心 | Pld抑制剂在制备治疗脊髓损伤的药物中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773423A (en) * | 1993-07-13 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| US5688774A (en) * | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| GB9723589D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| US6586413B2 (en) * | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| ATE336492T1 (de) * | 2000-01-14 | 2006-09-15 | Us Gov Health & Human Serv | Methonocarbacycloalkylanaloga von nucleosiden |
| EP1241176A1 (en) * | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
| US20090192077A1 (en) * | 2005-04-15 | 2009-07-30 | Shizuko Sei | North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus |
| WO2008156513A2 (en) * | 2007-03-29 | 2008-12-24 | University Of Connecticut | Methods to protect skeletal muscle against injury |
-
2005
- 2005-09-02 KR KR1020077006251A patent/KR20070050484A/ko not_active Abandoned
- 2005-09-02 BR BRPI0515030-2A patent/BRPI0515030A/pt not_active IP Right Cessation
- 2005-09-02 AU AU2005285284A patent/AU2005285284B2/en not_active Ceased
- 2005-09-02 WO PCT/US2005/031678 patent/WO2006031505A1/en not_active Ceased
- 2005-09-02 CN CN2005800363201A patent/CN101056879B/zh not_active Expired - Fee Related
- 2005-09-02 US US11/574,779 patent/US7825126B2/en not_active Expired - Fee Related
- 2005-09-02 EP EP05795036A patent/EP1794162A1/en not_active Withdrawn
- 2005-09-02 CA CA002601996A patent/CA2601996A1/en not_active Abandoned
- 2005-09-02 JP JP2007531262A patent/JP2008512457A/ja not_active Ceased
-
2007
- 2007-03-05 IL IL181716A patent/IL181716A0/en unknown
-
2012
- 2012-06-06 JP JP2012128779A patent/JP2012229215A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010515750A5 (enExample) | ||
| EP4458834A3 (en) | Heterocyclic glp-1 agonists | |
| CN1152041C (zh) | C－吡唑a2a受体激动剂 | |
| JP2006517939A5 (enExample) | ||
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| JP2012513990A5 (enExample) | ||
| JP2005053931A5 (enExample) | ||
| JP2011515398A5 (enExample) | ||
| JP2020530848A5 (enExample) | ||
| WO1998047505A9 (en) | Neuropeptide y receptor antagonist | |
| ZA202306748B (en) | Glp-1r receptor agonist compound and use thereof | |
| JP2011529917A5 (enExample) | ||
| LU92602I2 (fr) | Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci | |
| JP2011519374A5 (enExample) | ||
| EP4566670A3 (en) | Modulators of pharmacokinetic properties of therapeutics | |
| CN1277553A (zh) | 血管生成促进剂和血管生成增效剂 | |
| JP2002505337A5 (enExample) | ||
| MX2007008557A (es) | Derivados de purina que actuan como agonistas del receptor a2a. | |
| WO2006015860A3 (en) | Pyrazole derivatives for treating conditions mediated by activation of the adenosine a2b or a3 receptor | |
| WO2006052798B1 (en) | Method of treating pathological blushing | |
| MX2007011105A (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. | |
| CN1780615A (zh) | 氮杂环丁烷羧酰胺衍生物在疗法中的用途 | |
| JP2004522794A5 (enExample) | ||
| JP2012524110A5 (enExample) | ||
| JP2019535694A5 (enExample) |